These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24650006)

  • 21. Preparation of preformed porous PLGA microparticles and antisense oligonucleotides loading.
    Ahmed AR; Bodmeier R
    Eur J Pharm Biopharm; 2009 Feb; 71(2):264-70. PubMed ID: 18840521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction in burst release after coating poly(D,L-lactide-co-glycolide) (PLGA) microparticles with a drug-free PLGA layer.
    Ahmed AR; Elkharraz K; Irfan M; Bodmeier R
    Pharm Dev Technol; 2012; 17(1):66-72. PubMed ID: 20854130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles.
    Kumar PS; Ramakrishna S; Saini TR; Diwan PV
    Pharmazie; 2006 Jul; 61(7):613-7. PubMed ID: 16889069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Water-soluble betamethasone-loaded poly(lactide-co-glycolide) hollow microparticles as a sustained release dosage form.
    Chaw CS; Yang YY; Lim IJ; Phan TT
    J Microencapsul; 2003; 20(3):349-59. PubMed ID: 12881115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation and in vitro evaluation of etoposide-loaded PLGA microspheres for pulmonary drug delivery.
    Feng R; Zhang Z; Li Z; Huang G
    Drug Deliv; 2014 May; 21(3):185-92. PubMed ID: 24107001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification.
    Gasparini G; Kosvintsev SR; Stillwell MT; Holdich RG
    Colloids Surf B Biointerfaces; 2008 Feb; 61(2):199-207. PubMed ID: 17919891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery.
    Giovagnoli S; Blasi P; Schoubben A; Rossi C; Ricci M
    Int J Pharm; 2007 Mar; 333(1-2):103-11. PubMed ID: 17079101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical delivery of urea encapsulated in biodegradable PLGA microparticles: O/W and W/O creams.
    Haddadi A; Aboofazeli R; Erfan M; Farboud ES
    J Microencapsul; 2008 Sep; 25(6):379-86. PubMed ID: 18465299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery.
    Lee J; Oh YJ; Lee SK; Lee KY
    J Control Release; 2010 Aug; 146(1):61-7. PubMed ID: 20553775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model.
    Oh YJ; Lee J; Seo JY; Rhim T; Kim SH; Yoon HJ; Lee KY
    J Control Release; 2011 Feb; 150(1):56-62. PubMed ID: 21070826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
    Mundargi RC; Babu VR; Rangaswamy V; Patel P; Aminabhavi TM
    J Control Release; 2008 Feb; 125(3):193-209. PubMed ID: 18083265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preparation and evaluation of PLGA microparticles as carrier for the pulmonary delivery of rhIL-2 : I. Effects of some formulation parameters on microparticle characteristics.
    Devrim B; Bozkir A; Canefe K
    J Microencapsul; 2011; 28(6):582-94. PubMed ID: 21827360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies.
    Gavini E; Chetoni P; Cossu M; Alvarez MG; Saettone MF; Giunchedi P
    Eur J Pharm Biopharm; 2004 Mar; 57(2):207-12. PubMed ID: 15018976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues.
    Crotts G; Park TG
    J Microencapsul; 1998; 15(6):699-713. PubMed ID: 9818948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine.
    Bae SE; Son JS; Park K; Han DK
    J Control Release; 2009 Jan; 133(1):37-43. PubMed ID: 18838089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incorporation and release of vancomycin from poly(D,L-lactide-co-glycolide) microspheres.
    Atkins TW; Peacock SJ; Yates DJ
    J Microencapsul; 1998; 15(1):31-44. PubMed ID: 9463805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formulation of porous poly(lactic-co-glycolic acid) microparticles by electrospray deposition method for controlled drug release.
    Hao S; Wang Y; Wang B; Deng J; Zhu L; Cao Y
    Mater Sci Eng C Mater Biol Appl; 2014 Jun; 39():113-9. PubMed ID: 24863206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing the pH of the external aqueous phase may modulate protein entrapment and delivery from poly(lactide-co-glycolide) microspheres prepared by a w/o/w solvent evaporation method.
    Leo E; Pecquet S; Rojas J; Couvreur P; Fattal E
    J Microencapsul; 1998; 15(4):421-30. PubMed ID: 9651864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microsphere delivery of Risperidone as an alternative to combination therapy.
    D'Souza S; Faraj J; DeLuca P
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poly(D,L-lactide-co-glycolide) microspheres containing 5-fluorouracil: optimization of process parameters.
    Parikh RH; Parikh JR; Dubey RR; Soni HN; Kapadia KN
    AAPS PharmSciTech; 2003; 4(2):E13. PubMed ID: 12916895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.